These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 31562818)

  • 1. Early-stage endometrial cancer, CTNNB1 mutations, and the relation between lymphovascular space invasion and recurrence.
    Imboden S; Tapia C; Scheiwiller N; Kocbek V; Altermatt HJ; Janzen J; Mueller MD; McKinnon B
    Acta Obstet Gynecol Scand; 2020 Feb; 99(2):196-203. PubMed ID: 31562818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.
    Moroney MR; Davies KD; Wilberger AC; Sheeder J; Post MD; Berning AA; Fisher C; Lefkowits C; Guntupalli SR; Behbakht K; Corr BR
    Gynecol Oncol; 2019 Jun; 153(3):517-520. PubMed ID: 30910249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.
    Kurnit KC; Kim GN; Fellman BM; Urbauer DL; Mills GB; Zhang W; Broaddus RR
    Mod Pathol; 2017 Jul; 30(7):1032-1041. PubMed ID: 28281553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma.
    Ruz-Caracuel I; López-Janeiro Á; Heredia-Soto V; Ramón-Patino JL; Yébenes L; Berjón A; Hernández A; Gallego A; Ruiz P; Redondo A; Peláez-García A; Mendiola M; Hardisson D
    Virchows Arch; 2021 Dec; 479(6):1167-1176. PubMed ID: 34420090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
    Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
    Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters.
    Catasus L; Gallardo A; Cuatrecasas M; Prat J
    Mod Pathol; 2008 Feb; 21(2):131-9. PubMed ID: 18084252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant treatment in early-stage endometrial cancer: context-dependent impact of somatic
    Kurnit KC; Fellman BM; Mills GB; Bowser JL; Xie S; Broaddus RR
    Int J Gynecol Cancer; 2022 Jul; 32(7):869-874. PubMed ID: 35483739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
    Konopka B; Janiec-Jankowska A; Kwiatkowska E; Najmoła U; Bidziński M; Olszewski W; Goluda C
    Hum Pathol; 2011 Nov; 42(11):1710-9. PubMed ID: 21531001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is Surgical Staging Necessary for Patients with Low-risk Endometrial Cancer? A Retrospective Clinical Analysis.
    Kokcu A; Kurtoglu E; Celik H; Kefeli M; Tosun M; Onal M
    Asian Pac J Cancer Prev; 2015; 16(13):5331-5. PubMed ID: 26225674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical significance of lymphovascular space invasion in patients with low-risk endometrial cancer.
    Çakır İ; Gülseren V; Büyüktalancı E; Çakır ZE; Özer M; Ata C; Sancı M; Gökçü M; Erkılınç S; Güngördük K
    Rev Assoc Med Bras (1992); 2023; 69(7):e20221730. PubMed ID: 37466592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphovascular space invasion and the treatment of stage I endometrioid endometrial cancer.
    van der Putten LJ; Geels YP; Ezendam NP; van der Putten HW; Snijders MP; van de Poll-Franse LV; Pijnenborg JM
    Int J Gynecol Cancer; 2015 Jan; 25(1):75-80. PubMed ID: 25356534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.
    Cosgrove CM; Cohn DE; Hampel H; Frankel WL; Jones D; McElroy JP; Suarez AA; Zhao W; Chen W; Salani R; Copeland LJ; O'Malley DM; Fowler JM; Yilmaz A; Chassen AS; Pearlman R; Goodfellow PJ; Backes FJ
    Gynecol Oncol; 2017 Sep; 146(3):588-595. PubMed ID: 28709704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide single nucleotide polymorphism arrays as a diagnostic tool in patients with synchronous endometrial and ovarian cancer.
    Ikeda Y; Oda K; Nakagawa S; Murayama-Hosokawa S; Yamamoto S; Ishikawa S; Wang L; Takazawa Y; Maeda D; Wada-Hiraike O; Kawana K; Fukayama M; Aburatani H; Yano T; Kozuma S; Taketani Y
    Int J Gynecol Cancer; 2012 Jun; 22(5):725-31. PubMed ID: 22635024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. POLE mutation combined with microcystic, elongated and fragmented (MELF) pattern invasion in endometrial carcinomas might be associated with poor survival in Chinese women.
    He D; Wang H; Dong Y; Zhang Y; Zhao J; Lv C; Zheng X; Li D; Li T
    Gynecol Oncol; 2020 Oct; 159(1):36-42. PubMed ID: 32800323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphovascular Space Invasion as a Risk Factor in Early Endometrial Cancer.
    Sadozye AH; Harrand RL; Reed NS
    Curr Oncol Rep; 2016 Apr; 18(4):24. PubMed ID: 26922330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer.
    Malentacchi F; Turrini I; Sorbi F; Projetto E; Castiglione F; Fambrini M; Petraglia F; Pillozzi S; Noci I
    Oncol Rep; 2019 Mar; 41(3):1560-1574. PubMed ID: 30569174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of lymphovascular space invasion in low-risk endometrial cancer.
    Ayhan A; Şahin H; Sari ME; Yalçin I; Haberal A; Meydanli MM
    Int J Gynecol Cancer; 2019 Mar; 29(3):505-512. PubMed ID: 30665899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.
    Stelloo E; Nout RA; Osse EM; Jürgenliemk-Schulz IJ; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Nijman HW; Putter H; Bosse T; Creutzberg CL; Smit VT
    Clin Cancer Res; 2016 Aug; 22(16):4215-24. PubMed ID: 27006490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of exon 7 PTEN Gene in Endometrial Carcinoma.
    Kafshdooz L; Kafshdooz T; Tabrizi AD; Mohaddes Ardabili SM; Akbarzadeh A; Gharesouran J; Ghojazadeh M; Farajnia S
    Asian Pac J Cancer Prev; 2015; 16(11):4521-4. PubMed ID: 26107197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations.
    Konopka B; Janiec-Jankowska A; Czapczak D; Paszko Z; Bidziński M; Olszewski W; Goluda C
    J Cancer Res Clin Oncol; 2007 Jun; 133(6):361-71. PubMed ID: 17219201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.